Disc Medicine, a clinical-stage biopharmaceutical company, announced a $350 million public offering of common stock and pre-funded warrants, with an option for underwriters to buy an additional $52.5 million. The funds will support research, clinical development, and commercialization efforts for its treatments targeting serious hematologic diseases, including bitopertin for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP). The offering is subject to market conditions and regulatory approvals. This move aims to accelerate Disc Medicine's pipeline and prepare for potential product launches.
Disc Medicine's proposed $350 million public offering provides context for healthcare sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Oct 20, 2026 03:02 WIB: Of 150 priced health-sector US stocks, 87 rose and 62 fell today. Notable movers include MESO (Mesoblast Limited) at USD 11.96 with a -9.98% change and a typical hold time of 16 days, BNGO (BioNano Genomics Inc) at USD 1.25 with a -8.76% change and a 51-day hold time, and IBRX (ImmunityBio Inc. Common Stock) at USD 8.46 with a -7.84% change, Pluang order activity showing 33% sell and 67% buy, and a 2-day hold time.
Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...
